Alphamab Oncology (3NK.F)

0.2560 -0.0060 (-2.29%) At close: 08:14AM CEST

Alphamab Oncology

No. 175 Fangzhou Road
Suzhou Industrial Park
Suzhou
China

https://www.alphamabonc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 435

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Ting Xu Ph.D.	Founder, Executive Chairman & CEO	890.35k	N/A	1973
Ms. Yang Liu	VP of Corporate Operations & Executive Director	384.91k	N/A	1972
Ms. Jin'nan Wang	Director of Investor Relations & Joint Company Secretary	N/A	N/A	1983
Mr. Yumin Wan	Vice President of Government Affairs & Public Relations	N/A	N/A	1972
Dr. Mike Liu M.B.A., Ph.D.	Senior Vice President of Business Development	N/A	N/A	1966
Mr. Jing Han	Chief Commercial Officer	N/A	N/A	1973
Ms. Lok Yee Chan A.C.I.S., A.C.S.	Joint Company Secretary	N/A	N/A	1990

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase III clinical trials for treatment of HER2-positive breast cancer; and phase I and II clinical trial treatment of heavily pre-treated HER2 cancers, as well as Phase II clinical trial to treat unreselectable or metastatic HER2-positive solid tumors. The company's product pipeline also comprises KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for neoadjuvant/adjuvant treatment of non-small cell lung cancer and endometrial cancer; and KN019, a CTLA-4-based immunosuppressant fusion protein, for auto-immune diseases and oncology treatment-induced immune disorders. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody that prevents the immune escape of tumor cells; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

Corporate governance

Alphamab Oncology’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.